Eleusis to Become Public Company in Merger with Silver Spike Acquisition Corp. II (SPKB)

Beckley Psytech Acquires Eleusis Therapeutics Limited

October 24, 2022

Biotechnology

Beckley Psytech Limited has acquired 100% of Eleusis Therapeutics Limited in an all-equity transaction, adding Eleusis' clinical-stage assets (including ELE-101) and its R&D team to Beckley's pipeline. Eleusis CEO Shlomi Raz will join Beckley as Chief Business Officer as the companies integrate to accelerate development of short-duration psychedelic therapies.

Silver Spike Acquisition Corp. Completes Business Combination with WM Holding Company (Weedmaps)

June 16, 2021

Cloud & SaaS

WM Holding Company, LLC (Weedmaps), a technology and SaaS platform for the cannabis industry, completed its previously announced business combination with Silver Spike Acquisition Corp. The combined public company was renamed WM Technology, Inc. (ticker: MAPS) and the transaction provided approximately $579 million of gross proceeds (including a $325 million PIPE) to support scaling WM Business and expanding the Weedmaps marketplace.

Ginkgo Bioworks to Become Public Company via Business Combination with Soaring Eagle Acquisition Corp

May 11, 2021

AI & Machine Learning

Ginkgo Bioworks agreed to a business combination with special purpose acquisition company Soaring Eagle Acquisition Corp., which would result in Ginkgo becoming a publicly listed company. The transaction is expected to close in the third quarter of 2021 and is expected to provide up to $2.5 billion of gross cash proceeds, including $775 million from a PIPE.

SAB Biotherapeutics to Go Public via Merger with Big Cypress Acquisition Corp.

October 20, 2021

Biotechnology

SAB Biotherapeutics entered into a definitive business combination/merger agreement with Big Cypress Acquisition Corp. (a SPAC), with the combined company to operate as SAB Biotherapeutics and be listed on Nasdaq. Big Cypress stockholders approved the deal, and the transaction was expected to close on or about October 22, 2021, subject to customary conditions.

MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement for Tri-specific Nanobody Sonelokimab

October 4, 2021

Biotechnology

MoonLake Immunotherapeutics AG entered into a definitive business combination agreement with Helix Acquisition Corp. to create a publicly listed biotechnology company focused on advancing tri-specific nanobody sonelokimab for IL-17A/F-driven skin and joint diseases. The transaction is expected to close late in Q4 2021 or early in Q1 2022 and provides approximately $230 million in total proceeds, including cash in Helix’s trust account and a $115 million PIPE led by Cormorant Asset Management.

CoinShares Going Public Via $1.2 Billion SPAC Merger With Vine Hill Capital

September 9, 2025

Financial Services

CoinShares International entered into a definitive business combination agreement with Vine Hill Capital Investment, a NASDAQ-listed SPAC. Upon completion, CoinShares will become publicly listed in the United States under a newly formed entity, Odysseus Holdings Limited.